Le Lézard
Classified in: Health, Science and technology
Subject: Stock Sale/Buyback

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on February 28, 2022, the compensation committee of the Company's Board of Directors approved grants of non-qualified stock option awards to purchase an aggregate of 198,300 shares of its common stock to three new employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended (the "Inducement Plan"). The stock options were granted as an inducement material to the new employees' becoming employees of ImmunoGen in accordance with Nasdaq Listing Rule 5635(c)(4).

The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of ImmunoGen (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with ImmunoGen, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

The options have an exercise price of $5.64 per share, which is equal to the closing price of ImmunoGen's common stock on the Nasdaq Global Select Market on February 28, 2022. Each option will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant, subject to such employee's continued employment with ImmunoGen on such vesting dates. Each option is subject to the terms and conditions of the Inducement Plan and the terms and conditions of a stock option agreement covering the grant.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOWtm.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.


These press releases may also interest you

at 06:50
Reata Pharmaceuticals, Inc. ("Reata," the "Company," "our," "us," or "we"), a clinical-stage biopharmaceutical company, announced that on August 8, 2022, after the U.S. financial markets closed, we received a communication from the U.S. Food and...

at 06:50
Avaya Holdings Corp. ("Avaya" or "the Company") today reported selected additional preliminary financial results for the third quarter of fiscal 2022 ended June 30, 2022. All financial results for the third quarter ended June 30, 2022 and related...

at 06:45
The "Denmark Gift Card and Incentive Card Market Intelligence and Future Growth Dynamics (Databook) - Q1 2022 Update" report has been added to ResearchAndMarkets.com's offering. The gift card market in the country will increase from US$862.2 million...

at 06:43
Infortrend® Technology, Inc. (TWSE: 2495), the industry-leading enterprise storage provider, released their flagship EonStor GS all-flash unified storage systems. Featuring the latest Intel Xeon D CPU, PCIe Gen4, and 100GbE, the solutions are perfect...

at 06:35
Novo Integrated Sciences, Inc., a NASDAQ listed company operating in the GTA ("Novo"), is pioneering the delivery of non-catastrophic healthcare in both Canada and the U.S. through the integration of medical technology, innovative diagnostic and...

at 06:30
, Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the market leader in full-spectrum hemp extract wellness products, today reported financial results for the second quarter ended June 30, 2022....



News published on 1 march 2022 at 16:35 and distributed by: